标题
Targeting FLT3 Mutations in Acute Myeloid Leukemia
作者
关键词
-
出版物
Cells
Volume 7, Issue 1, Pages 4
出版商
MDPI AG
发表日期
2018-01-09
DOI
10.3390/cells7010004
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML
- (2016) Steven Knapper et al. BLOOD
- A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activatingFLT3mutations
- (2015) Walter Fiedler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia
- (2014) H. K. Lee et al. BLOOD
- Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
- (2014) D. C. Linch et al. BLOOD
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Reversal of Acquired Drug Resistance in FLT3-Mutated Acute Myeloid Leukemia Cells via Distinct Drug Combination Strategies
- (2014) W. Zhang et al. CLINICAL CANCER RESEARCH
- Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML
- (2014) Giridharan Ramsingh et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- AMG 925 Is a Dual FLT3/CDK4 Inhibitor with the Potential to Overcome FLT3 Inhibitor Resistance in Acute Myeloid Leukemia
- (2014) C. Li et al. MOLECULAR CANCER THERAPEUTICS
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
- (2013) M. Pratcorona et al. BLOOD
- Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy
- (2013) Naval Daver et al. Clinical Lymphoma Myeloma & Leukemia
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Overcoming AC220 resistance of FLT3-ITD by SAR302503
- (2013) M Kesarwani et al. Blood Cancer Journal
- Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation
- (2012) Elisabeth Zirm et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
- (2012) R M Stone et al. LEUKEMIA
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
- (2011) Aref Al-Kali et al. Clinical Lymphoma Myeloma & Leukemia
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug resistance in mutant FLT3-positive AML
- (2010) E Weisberg et al. ONCOGENE
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Mechanisms of resistance to FLT3 inhibitors
- (2009) S. Haihua Chu et al. DRUG RESISTANCE UPDATES
- Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells
- (2008) E. Weisberg et al. BLOOD
- Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML
- (2008) Z. Zeng et al. BLOOD
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Blockade of MEK/ERK signaling enhances sunitinib-induced growth inhibition and apoptosis of leukemia cells possessing activating mutations of the FLT3 gene
- (2007) Chie Nishioka et al. LEUKEMIA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started